Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $558,423 | $560,762 | $540,260 | $571,068 |
| - Cash | $63,560 | $84,578 | $92,997 | $77,851 |
| + Debt | $241 | $244 | $34,229 | $0 |
| Enterprise Value | $495,104 | $476,428 | $481,492 | $493,217 |
| Revenue | $467 | $68,737 | $77,231 | $76,369 |
| % Growth | -99.3% | -11% | 1.1% | – |
| Gross Profit | $256 | $37,118 | $46,096 | $42,234 |
| % Margin | 54.7% | 54% | 59.7% | 55.3% |
| EBITDA | $103 | $12,070 | $18,485 | $15,830 |
| % Margin | 22.1% | 17.6% | 23.9% | 20.7% |
| Net Income | $54 | $5,878 | $8,791 | $8,693 |
| % Margin | 11.7% | 8.6% | 11.4% | 11.4% |
| EPS Diluted | 0.16 | 17.28 | 25.69 | 25.22 |
| % Growth | -99.1% | -32.7% | 1.9% | – |
| Operating Cash Flow | $40 | $54 | $18,890 | $13,730 |
| Capital Expenditures | -$10 | -$13 | -$927 | -$3,056 |
| Free Cash Flow | $29 | $41 | $17,963 | $10,674 |